



Where Others See Complexity
**WE SEE HOPE FOR
PATIENTS AND FAMILIES**

Who We Are

Mallinckrodt is a company united around a powerful mission - **Managing Complexity. Improving Lives.** This is our passion and the core of who we are. As a biopharmaceutical company we manage complexity on a daily basis and don't shy away from challenges. Rather, we see complexity as an opportunity to change lives.

A COMPANY IN TRANSFORMATION

Founded in 1867, Mallinckrodt has been advancing the fields of science and medicine for more than 150 years. Since becoming independent again in 2013, Mallinckrodt has undergone transformational change and has emerged as a patient-focused biopharmaceutical company with a diverse portfolio of innovative products and a promising pipeline.

OUR VISION FOR THE FUTURE

Today, we see ourselves as an **innovation-driven biopharmaceutical growth company focused on improving outcomes for underserved patients with severe and critical conditions.** This vision serves as our roadmap for success and brings into sharper focus the real meaning of what we do everyday — working together to improve the lives of patients.

We are guided by a set of four values: **patient-centric, integrity, innovative and collaborative.** These values are the foundation of our company and empower us to achieve our mission and vision.

COMMITTED TO BUILDING A BETTER TOMORROW

Being a responsible company is a vital part of being a good corporate citizen. At Mallinckrodt, this means advocating for patient health and access to medicines, building stronger and safer communities and employing sustainable business practices. And, as a company that values a diverse workforce, we support initiatives to ensure that every employee works in an environment that promotes individual dignity and respect. Mallinckrodt has earned recognition as being a top place to work and a leading company for inclusion and diversity.

Learn more at Mallinckrodt.com



Founded

1867

4 Values
Patient-Centric
Integrity
Innovative
Collaborative

3400+
Employees
Worldwide

20+
Drug Development
Programs




PATIENTS ARE AT THE HEART OF EVERYTHING WE DO

Mallinckrodt is focused on developing innovative therapies and cutting-edge technologies for underserved patients with severe and critical conditions.

SPECIALTY BRANDS AREAS OF FOCUS

- Autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology
- Immunotherapy and neonatal respiratory critical care therapies
- Analgesics
- Gastrointestinal products

2018 PRODUCT MIX¹
Total Net Sales of \$3.2 billion²



CORPORATE SOCIAL RESPONSIBILITY

Our commitment to corporate responsibility goes beyond making quality products.



Prescription Drug Safety

Mallinckrodt donated more than two million drug deactivation pouches to patients and communities to help dispose of unused opioid medications.



Philanthropy

We advance society through our charitable giving, employee matching gift and volunteer programs in focus areas of health and wellness, science education, life sciences and anti-drug initiatives.



Public Policy

Quality healthcare should be available to every patient who needs it. We advocate for policies that promote drug discovery, remove barriers to treatment and focus on patient care.



Access to Medicines

We offer prescription assistance programs to help qualifying patients with little or no drug coverage get medicines at no cost, or at a reduced cost.



Patient Advocacy

We collaborate with third party organizations to advance education, raise disease awareness and develop ways to impact patients' lives.



Sustainability

We believe in being a socially responsible community partner. This means growing our business by setting corporate sustainability goals for the future, built upon industry-leading initiatives.

¹ Acthar Gel (repository corticotropin); INOMAX (nitric oxide) gas, for inhalation; OFIRMEV (acetaminophen) injection; Therakos immunology platform; AMITIZA (lubiprostone)
² Last twelve months' net sales ended December 28, 2018 on an as-reported basis, including AMITIZA since February 2018
³ On Sept. 10, 2019, Mallinckrodt announced definitive agreement to sell BioVectra Inc. to affiliate of H.I.G. Capital for approximately \$250 million, with closing expected in fourth quarter 2019
Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. © 2019 Mallinckrodt Pharmaceuticals. 9/19